Drug intelligence / Profile preview

Metosafe-AM

Development stage: Unknown
Lead developer: Zinnia Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

Metosafe-AM is a fixed-dose combination tablet developed by Zinnia Life Sciences for the management of hypertension and cardiovascular disease. It combines metoprolol succinate, a beta-1 selective adrenergic receptor blocker in an extended-release (ER) formulation, with amlodipine, a dihydropyridine L-type voltage-gated calcium channel blocker. Metoprolol reduces heart rate and cardiac contractility, while amlodipine induces vasodilation by decreasing vascular resistance. This synergistic combination is designed for once-daily oral administration to improve blood pressure control in patients requiring dual therapy.

Brand names: Metosafe-AM
Other names: metoprolol ER + amlodipinemetoprolol succinate ER + amlodipine

Targets

LTCC (Voltage-gated calcium channel (L-type))ADRB1 (β1)

Beyond the preview

Go deeper on Metosafe-AM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metosafe-AM.

Explore the full profile